Diffuse Large B-Cell Lymphoma: Treatment Beyond R-CHOP

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Interpret the findings from clinical trials on the use of novel therapeutic strategies and how these strategies can be incorporated into current treatment paradigms
Additional information
Supporters: 

Supported by educational grants from Foundation Medicine, Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Pharmacyclics, Inc. and Janssen Biotech, Inc.; and Takeda Oncology

Course summary
Available credit: 
  • 0.50 Participation
  • 0.50 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician
Course opens: 
11/06/2014
Course expires: 
11/06/2015
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 9th Annual Congress: Hematologic Malignancies™

Leo I. Gordon, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Available Credit

  • 0.50 Participation
  • 0.50 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing